Friday, December 9, 2011

Patient Advocate Foundation Announces $9.3 Million Donation to their Co-Pay Relief (CPR) Program

WASHINGTON, Dec. 9, 2011 /PRNewswire via COMTEX/ -- Additional Funding to CPR Program Will Serve Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Colon Cancer, Rheumatoid Arthritis, Hepatitis C Patients in Need of Financial Assistance

Patient Advocate Foundation (PAF) is pleased to announce that it has received a $9.3 million contribution, from an existing partner, providing further support through its Co-Pay Relief Program (CPR) for patients suffering from nonsquamous non-small cell lung cancer (NSCLC), breast cancer, colon cancer, rheumatoid arthritis and hepatitis C who are unable to afford their medical co-payments. These funds are currently available to qualified patients.

PAF's CPR Program provides direct financial support for pharmaceutical co-payments to insured patients, including Medicare Part D beneficiaries, who financially and medically qualify. Since the program's inception in April 2004, CPR has distributed more than $130 million in assistance to more than 50,000 patients nationwide who were unable to afford their pharmaceutical co-payments.

"The Co-Pay Relief Program was developed after PAF recognized extreme increases each year in the number of patients seeking pharmaceutical co-pay assistance, despite the fact they were insured," said Nancy Davenport-Ennis, Founder and CEO of PAF. "Battling any disease is difficult, particularly now with the high out-of-pocket expenses that are routinely incurred by patients. Thanks to this extremely generous donation, we will be able to offer an even greater level of support to patients seeking help with their pharmaceutical co-payments."

On August 1, 2011, PAF announced a new operational model for CPR that serves more patients, provides enhanced service to both providers and patients through new technology tools, and allows for many more patient approvals. CPR donations are now released in total into each disease silo immediately upon receipt, rather than dividing contributions across a twelve month period. CPR accepts all qualified new and renewal applications on a first come first serve basis with no limit imposed on the number of approvals issued monthly. CPR also accepts and processes all expenditures on a first come, first serve basis until the available funds in the entire silo are exhausted. Eligible expenditures may be submitted by patients, providers and/or pharmacists.

"We are excited about CPR's use of state-of-the-art technology solutions to deliver a high degree of automation and efficiency to program users. For example, electronic signature and file upload capabilities have been integrated into both the online application and the expenditure submission processes, including the capability for a user to fax documents which use a barcode based routing system," said Beth Patterson, President of Mission Delivery, and Fran Castellow, President of Operations. "These technological enhancements allow the patient, provider and pharmacy communities to leverage existing Electronic Health Records (EHR) or their Health Information Technology (HIT) to increase the speed with which their expenditures and applications are processed. In addition, CPR still has secure web-based portal access 24 hours a day, online assistance capabilities and live assistance via the toll-free phone number."

Patient Advocate Foundation and its companion organization, the National Patient Advocate Foundation (NPAF), were founded on the principle that health care is a basic human need and shared social responsibility. Annually, PAF receives thousands of contacts requesting information and assistance via their toll-free hotline, as well as online, with complete direct, sustained case management services provided to patients from all fifty states free of charge. For more information about PAF, visit or call toll free (800) 532-5274. For more information about PAF's Co-Pay Relief Program visit or call toll free (866) 512-3861.

Patient Advocate Foundation

Copyright (C) 2011 PR Newswire. All rights reserved

No comments:

Post a Comment